Company news

UroGen Pharma Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

January 16, 2024

UroGen Pharma to Participate in the B. Riley Healthcare Conference

January 10, 2024

UroGen Pharma Reports Third Quarter 2023 Financial Results

November 13, 2023

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

November 12, 2023

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

November 6, 2023

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

October 2, 2023

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

August 9, 2023

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 7, 2023

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 1, 2023

UroGen Announces $120 Million Private Placement of Ordinary Shares

July 26, 2023

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

July 26, 2023

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

July 24, 2023

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

July 9, 2023

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

July 5, 2023

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

June 19, 2023

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 8, 2023

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 10, 2023

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

May 3, 2023

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

April 30, 2023

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

April 29, 2023

UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

April 24, 2023

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

March 15, 2023

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

March 8, 2023

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

February 14, 2023

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 10, 2023

UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

December 18, 2022

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

December 1, 2022

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer

November 30, 2022

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

November 20, 2022

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

November 13, 2022

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 9, 2022

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

November 8, 2022

UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 2, 2022

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers

October 10, 2022

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution

September 27, 2022

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors

September 11, 2022

UroGen Pharma Announces Upcoming 2022 Conferences

September 6, 2022

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 10, 2022

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 26, 2022

UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer

May 15, 2022

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

May 12, 2022

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 9, 2022

UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

May 2, 2022

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

March 28, 2022

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

March 20, 2022

UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven

March 7, 2022

UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022

March 3, 2022

UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

February 28, 2022

UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference

February 27, 2022

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

February 9, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.